不同化疗途径对中晚期胰腺癌治疗价值的分析

目的:评价不同化疗途径对中晚期胰腺癌的治疗价值。方法:对12例单纯行静脉化疗、13例行区域性动脉化疗,17例区域性动脉化疗联合全身静脉化疗患者的临床受益反应、客观疗效、不良反应以及生存期进行分析。结果:三组病例的临床受益率分别为25.0%、61.5%和76.5%(P<0.05);有效治疗率为33.3%、46.2%和64.7%(P>0.05);出现严重不良反应的病例分别为3例、1例和1例(P>0.05);中位生存时间分别为8.0、9.0、11.5个月(P<0.05)。结论:区域性动脉化疗联合全身静脉化疗可提高中晚期胰腺癌患者的临床收益率,获得较好疗效,并可延长患者生存期。

Therapeutic Value of Different Chemotherapy Route on the Advanced Pancreatic Carcinoma

Objective To evaluate the therapeutic value of different chemotherapy route on the advanced pancreatic carcinoma. Methods Twelve cases were given intravenous chemotherapy, 13 cases were given regional arterial chemotherapy, 17 cases were given regional arterial chemotherapy combined with intravenous chemotherapy, the clinical beneficial response, objective response, side effects and survival time of all the patients were analyzed. Results The clinical beneficial response rates of three groups were 25.0% ,61.5% and 76.5% ,respectively （P 〈 0.05 ） ;the effective rates were 33.3% ,46.2% and 64.7% ,respectively （P 〉 0.05） ; there were 3,1,1 cases demonstrating serious adverse reaction in three groups, respectively. The median survival time were 8.0,9.0 and 11.5 months, respectively （ P 〈 0.05 ）. Conclusion Regional arterial chemotherapy combined with intravenous chemotherapy could enhance the clinical beneficial response rate and effectively prolong the survival time of patients with advanced pancreatic carcinoma.